A five-year follow-up narrative highlights how CAR-T therapy continues to surprise investigators in autoimmune disease, centered on a case treated around Georg Schett’s research program. The story describes how early concerns about whether CAR-T could worsen autoimmunity were outweighed by clinical outcomes in a young lupus patient—who reportedly entered and sustained remission. The case helped drive renewed research interest in using engineered T cells for autoimmune targets, with additional preclinical work from investigators including Fabian Müller at University of Erlangen-Nuremberg supporting the biology behind the approach. The continued remission provides a durable data point for a space where durable efficacy, safety, and patient selection remain key unknowns. While a single-patient experience does not define a standard of care, the long tail of follow-up is exactly what investors and researchers look for when evaluating whether autoimmune CAR-T can translate beyond early exploratory reports.